Phase 2 trial in 164 patients with combined post- and precapillary pulmonary hypertension in HFpEF: sotatercept 0.3 mg/kg cut pulmonary vascular resistance vs placebo at 24 weeks (shift -1.02 Wood units); 0.7 mg/kg shift -0.75 (95% CI -1.52 to 0.03).
RCTn = 164
Gomberg-Maitland et al. Sotatercept for Combined Post- and Precapillary Pulmonary Hypertension Associated With Heart Failure: Results From the Phase 2, Randomized, Placebo-Controlled CADENCE Study